RxDoctor Payments Data

Ryan Allen-Brady

Family · Phoenix, AZNPI 1134691173

Payments from drug & device makers

$762in general payments, 2019–2025

Across 36 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hikma Pharmaceuticals USA$188
  • Protega Pharmaceutials Inc$130
  • Amgen$117
  • Boston Scientific$97
  • Collegium Pharmaceutical, Inc.$71
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$65786%
  • Education$10514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Hikma Pharmaceuticals USA10$188
Protega Pharmaceutials Inc4$130
Amgen5$117
Boston Scientific4$97
Collegium Pharmaceutical, Inc.5$71
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$35
AbbVie1$29
Nalu Medical, Inc.1$25
Otto Bock Healthcare LP1$22
Virtus Pharmaceuticals LLC1$19
Novartis1$15
Redhill Biopharma Inc.1$13

How this compares

$762 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$64,393
Medicare patients
288
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen494$22,223
Oxycodone Hcl914$17,701
MovantikNaloxegol Oxalate33$14,184
BelbucaBuprenorphine Hcl21$11,552
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen332$11,522
Gabapentin628$8,927
Xtampza ErOxycodone Myristate22$7,156
OxycontinOxycodone Hcl16$6,439
Lidocaine96$6,285
Lidocaine-PrilocaineLidocaine/Prilocaine41$5,594
Pregabalin161$5,447
Tizanidine Hcl487$5,434
Diclofenac Sodium135$4,045
Morphine Sulfate ErMorphine Sulfate176$3,904
Buprenorphine12$3,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$71$18,70843 claims
Redhill Biopharma Inc.Movantik$13$14,18433 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$188$5,32265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →